The role of the endothelium in systemic inflammatory response syndrome and sepsis

Endothelial Biomedicine

Volumn , Issue , 2007, Pages 1294-1302

  Hoesel, Laszlo M ^a   Ward, Peter A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861396628     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511546198.142     Document Type: Chapter

References (72)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348(16):1546-1554.
2. Angus DC, Linde-Zwirble, W.T., Lidicker, J. et al. Epidemiology of severe sepsis in theUnited States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303-1310.
3. Hack CE, Zeerleder S. The endothelium in sepsis: source of and a target for inflammation. Crit CareMed. 2001;29(7 Suppl):S21-S27.
4. Bone RC, Fisher CJ Jr., Clemmer TP, et al. Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med. 1989;17(5):389-393.
5. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644-1655.
6. Levy MM, Fink MP, Marshall. JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003;29(4):530-538.
7. Abraham E, Wunderink, R. Silverman, H. et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995;273(12):934-941.
8. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248-251.
9. Bone. RC, Sir Isaac. Newton, sepsis, SIRS, and CARS. Crit Care Med. 1996;24(7):1125-1128.
10. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348(2):138-150.
11. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA. 1989;86(9):3375-3378.
12. Cohnheim J. Lectures in General Pathology (Translated byMcKee AD from the second German edition). Vol. 1: New Sydenham Society, 1889.
13. Clark ER, Clark EL. Observations on changes in blood vascular endothelium in the living animal. Am J Anat. 1935;57:385-438.
14. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J. 1994;8(8):504-512.
15. McEver RP, Beckstead JH, Moore KL, et al. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest. 1989;84(1):92-99.
16. Mulligan MS, Schmid E, Till GO, et al. C5a-dependent upregulation in vivo of lung vascular P-selectin. J Immunol. 1997; 158(4):1857-1861.
17. Bless NM, Tojo SJ, Kawarai H, et al. Differing patterns of Pselectin expression in lunginjury.AmJPathol. 1998;153(4):1113-1122.
18. Asimakopoulos G, Taylor KM. Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules. Ann Thorac Surg. 1998;66(6):2135-2144.
19. Muller WA, Weigl SA, Deng X, Phillips DM. PECAM-1 is required for transendothelial migration of leukocytes.J ExpMed. 1993;178(2):449-460.
20. Vaporciyan AA, DeLisser HM, Yan HC, et al. Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science. 1993;262(5139):1580-1582.
21. Marchesi VT, Gowans. JL. The migration of lymphocytes through the endothelium of venules in lymph nodes: an electron microscope study. Proc R Soc Lond B Biol Sci. 1964;159:283-290.
22. Engelhardt B, Wolburg H.Mini-review: transendothelial migration of leukocytes: through the front door or around the side of the house? Eur J Immunol. 2004;34(11):2955-2963.
23. von Andrian UH, Chambers JD, McEvoy LM, et al. Two-step model of leukocyte-endothelial cell interaction in inflammation: distinct roles for LECAM-1 and the leukocyte beta 2 integrins in vivo. Proc Natl Acad Sci USA. 1991;88(17):7538-7542.
24. Simon SI, Chambers JD, Sklar LA. Flow cytometric analysis and modeling of cell-cell adhesive interactions: the neutrophil as a model. J Cell Biol. 1990;111(6 Pt 1):2747-2756.
25. Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J. 1995;9(10):946-55.
26. Iversen N, Sandset PM, Abildgaard U, Torjesen PA. Binding of tissue factor pathway inhibitor to cultured endothelial cellsinfluence of glycosaminoglycans. Thromb Res. 1996;84(4):267-278.
27. Mertens G, Cassiman JJ, Van den Berghe H, et al. Cell surface heparan sulfate proteoglycans from human vascular endothelial cells.Core protein characterization and antithrombin III binding properties. J Biol Chem. 1992;267(28):20435-20443.
28. Weksler BB, Marcus AJ, Jaffe EA. Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci USA. 1977;74(9):3922-3926.
29. Ihrcke NS, Wrenshall LE, Lindman BJ, Platt JL, Role of heparin sulfate in immune system-blood vessel interactions. Immunol Today. 1993;14(10):500-505.
30. Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood. 1989;73(1):159-165.
31. Moore KL, Andreoli SP, Esmon NL, et al. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest. 1987;79(1):124-130.
32. Preissner KT, Nawroth PP, Kanse SM. Vascular protease receptors: integrating haemostasis and endothelial cell functions. J Pathol. 2000;190(3):360-372.
33. Combes V, Simon AC, Grau GE, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest. 1999;104(1): 93-102.
34. Furchgott RF, Cherry PD, Zawadzki JV, Jothianandan D. Endothelial cells as mediators of vasodilation of arteries. J Cardiovasc Pharmacol. 1984;6(Suppl 2):S336-S343.
35. Yanagisawa M, Kurihara H, Kimura S, et al. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J Hypertens Suppl. 1988;6(4):S188-S191.
36. Marsden PA, Schappert KT, Chen HS, et al. Molecular cloning and characterization of human endothelial nitric oxide synthase. FEBS Lett. 1992;307(3):287-293.
37. Gross SS, Kilbourn RG, Griffith OW. NO in septic shock: good, bad or ugly? Learning from iNOS knockouts. Trends Microbiol. 1996;4(2):47-49.
38. Wanecek M, Weitzberg E, Rudehill A, Oldner A. The endothelin system in septic and endotoxin shock. Eur J Pharmacol. 2000; 407(1–2):1-15.
39. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003;101(10):3765–3777.
40. Peters K, Unger RE, K Brunner J Kirkpatrick CJ.Molecular basis of endothelial dysfunction in sepsis. CardiovascRes. 2003;60(1):49-57.
41. El-Samalouti VT, Schletter J, Brade H, et al. Detection of lipopolysaccharide (LPS)-binding membrane proteins by immuno-coprecipitation with LPS and anti-LPS antibodies. Eur J Biochem. 1997;250(2):418-424.
42. Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature. 1991;349(6310):614-617.
43. Foreman KE, Vaporciyan AA, Bonish BK, et al. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest. 1994;94(3):1147-1155.
44. Laudes IJ, Chu JC, Huber-Lang M, et al. Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol. 2002;169(10):5962–5970.
45. Varani J, Ward PA. Mechanisms of endothelial cell injury in acute inflammation. Shock. 1994;2(5):311-319.
46. Dinarello CA. Proinflammatory cytokines. Chest. 2000;118(2): 503-508.
47. Joyce DE, Nelson DR, Grinnell BW. Leukocyte and endothelial cell interactions in sepsis: relevance of the protein C pathway. Crit Care Med. 2004;32(Suppl 5):S280-S286.
48. Laudes IJ, Chu JC, Sikranth S, et al. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol. 2002;160(5):1867–1875.
49. Bombeli T, Mueller M, Haeberli A. Anticoagulant properties of the vascular endothelium. Thromb Haemost. 1997;77(3):408–423.
50. Bevilacqua MP, Pober JS, Majeau GR, et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparisonwith the actions of interleukin 1. Proc Natl Acad Sci USA. 1986;83(12): 4533-4537.
51. Schleef RR, Bevilacqua MP, Sawdey M, et al. Cytokine activation of vascular endothelium. Effectsontissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem. 1988;263(12):5797-5803.
52. Macias WL, Yan SB, Williams MD, et al. New insights into the proteinCpathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit Care. 2005;9(Suppl 4): S38-S45.
53. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial proteinCactivation in severemeningococcal sepsis.NEngl JMed. 2001;345(6):408-416.
54. Ganopolsky JG, Castellino FJ. A protein C deficiency exacerbates inflammatory and hypotensive responses in mice during polymicrobial sepsis in a cecal ligation and puncture model.AmJ Pathol. 2004;165(4):1433-1446.
55. Gu JM, Katsuura Y, Ferrell GL, Grammas P, Esmon CT. Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo. Blood. 2000;95(5):1687-1693.
56. Riedemann NC, Guo RF, Ward PA.Novel strategies for the treatment of sepsis. Nat Med. 2003;9(5):517-524.
57. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med. 1999;27(4): 723-732.
58. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis.NEngl J Med. 2001;344(10):699-709.
59. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345(19): 1359-1367.
60. Smith CW. Endothelial adhesion molecules and their role in inflammation. Can J Physiol Pharmacol. 1993;71(1):76-87.
61. Mayadas TN, Johnson RC, Rayburn H, et al. Leukocyte rolling and extravasation are severely compromised in P selectindeficient mice. Cell. 1993;74(3):541-554.
62. Wolitzky B, Kwee L, Terry R, et al. Targeted disruption of the murine E-selectin and VCAM-1 genes. J Cell Biochem. 1994; (Suppl 18A):300.
63. Tedder TF, Steeber DA, Pizcueta P. L-selectin-deficient mice have impaired leukocyte recruitment into inflammatory sites. J Exp Med. 1995;181(6):2259-2264.
64. Sligh JE Jr., Ballantyne CM, Rich SS, et al. Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1. ProcNatl Acad Sci USA. 1993;90(18):8529-8533.
65. Wilson RW, Ballantyne CM, Smith CW, et al. Gene targeting yields a CD18-mutant mouse for study of inflammation. J Immunol. 1993;151(3):1571-1578.
66. Schmits R, Kundig TM, Baker DM, et al. LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor. J Exp Med. 1996;183(4):1415-1426.
67. Lu H, Smith CW, Perrard J, et al. LFA-1 is sufficient in mediating neutrophil emigration in Mac-1-deficient mice. J Clin Invest. 1997;99(6):1340-1350.
68. Mercurio AM. Lessons from the alpha2 integrin knockout mouse. Am J Pathol. 2002;161(1):3-6.
69. Artis D, Humphreys NE, Potten CS, et al. Beta7 integrin-deficient mice: delayed leukocyte recruitment and attenuated protective immunity in the small intestine during enteric helminth infection. Eur J Immunol. 2000;30(6):1656-1664.
70. Anderson DC, Schmalsteig FC, Finegold MJ, et al. The severe and moderate phenotypes of heritableMac-1, LFA-1 deficiency: their quantitative definition and relation to leukocyte dysfunction and clinical features. J Infect Dis. 1985;152(4):668-689.
71. Etzioni A, Harlan JM, Pollack S, et al. Leukocyte adhesion deficiency (LAD) II: a new adhesion defect due to absence of sialyl lewis x, the ligand for selectins. Immunodeficiency. 1993;4(1-4):307-308.
72. von Andrian UH, Berger EM, Ramezani L, et al. In vivo behavior of neutrophils fromtwopatientswith distinct inheritedleukocyte adhesion deficiency syndromes. J Clin Invest. 1993;91(6):2893-2897.